Clinical Trials
12 trialsNCT01843868 2024-08-07
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Australasian Leukaemia and Lymphoma Group
Phase NA Withdrawn
NCT01851369 2024-05-08
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00871910 2017-10-23
Phase 1 Every-3-Week Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04630)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01625455 2017-05-10
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Vanderbilt University Medical Center
Phase 4 Terminated
NCT00248547 2017-05-09
Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
OHSU Knight Cancer Institute
Phase NA Completed
NCT00600353 2017-03-09
Multi-day Doses in Prevention of Nausea and Emesis
University of Kansas Medical Center
Phase 2 Completed
NCT02576327 2016-12-30
A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation
Peking University
Phase 4 Unknown
NCT00293384 2016-03-15
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT02347878 2015-01-27
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
Sun Yat-sen University
Phase 4 Unknown
NCT00651755 2013-07-02
Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
M.D. Anderson Cancer Center
Phase NA Completed
NCT00499668 2013-04-02
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Vanderbilt-Ingram Cancer Center
Phase NA Withdrawn
NCT00415103 2009-09-18
AMENO-2
PETHEMA Foundation
Phase 4 Completed